A study of the endogenous opioid system in the sudden infant death syndrome by Kuich, T. E. & Franciosi, R. A.
Medical Hypotheses 10: 365-384, 1983 
A STUDY OF THE ENDOGENOUS OPIOID SYSTEM IN THE 
SUDDEN INFANT DEATH SYNDROME 
T.E. Kuich, M.D.,* Department of Psychiatry, University 
of Michigan Medical School, Ann Arbor, Michigan 48105 
R.A. Franciosi, M.D., Department of Pediatric Pathology, 
Minneapolis Children's Health Center and Hospital, Minne- 
apolis, Minnesota 
ABSTRACT 
To investigate the possible role of the endogenous opioid 
system in the pathogenesis of the sudden infant death syndrome 
(SIDS) we measured met-enkephalin immunoreactivity by radioimmuno- 
assay in brain, lung, and adrenal glands of SIDS victims and of 
infants (controls) dying of nonneurologic causes. Met-enkephalin 
was stable in brain tissue up to 24 hours after death. On inspec- 
tion, met-enkephalin levels in the cerebral cortex of SIDS victims 
were similar to those in controls. Levels in the caudate nucleus 
were lower in infants than in adults. In the medulla, the levels 
in SIDS cases and controls were not found to differ significantly. 
The linear relationship between the levels in the medulla and age 
was not detectably different in SIDS and controls. However, as a 
subset, levels in the control group significantly decreased with 
increasing age (P = O.OOS), whereas levels in the SIDS group showed 
no correlation wTth age (P = 0.33). Levels of met-enkephalin in 
the adrenal gland of SIDSvictims were similar to those in controls 
and were considerably lower than adult values, Lung tissue was 
assayed for beta-endorphin immunoreactivity and met-enkephalin: 
for both peptides the values in SIDS cases were low (femtomolar 
range) and similar to those in controls. These data suggest that 
met-enkephalin is not markedly overproduced in brains of SIDS 
victims. Future postmortem studies should focus on more subtle 
evidence of endogenous opioid overactivity such as differences in 
age related changes, receptor number, and levels of other endogenous 
opioid peptides. 
INTRODUCTION 
Each year in the United States 7,000 to 8,000 lives are lost 
as a result of the sudden infant death syndrome (S1DSj.l SIDS 
is tie sudden, unexpected death of an apparently healthy infant in 
whom a :-outine autopsy fails to reveal the cause of death. It 
usually otc":~rs while the infant is thought to be asleep. In the 
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United States and many developed countries, SIDS is the most common 
cause of death among infants between one month and 12 months of 
age.2 Considerable evidence suggests that most SIDS victims were 
hypoxemic for weeks or months before death.lg3a4 It is now 
generally agreed that abnormal ventilatory control, leading to 
protracted apnea, especially during sleep, may be part of the 
pathogenic mechanism in many instances of SIDS.~,~ Current 
research strategies, therefore, have focused on the neural regula- 
tion of ventilation during infancy 697 Some investigators 
have suspected that a neurochemical abnormality may be the cause of 
the abnormal ventilatory control.8,9 However, few studies of 
neurochemistry have been done in SIDS.3 
The unconsciousness, respiratory depression and fatal respir- 
atory arrest that result from morphine overdose 16 and the know- 
ledge that therapeutic doses of morphine significantly depress 
hypoxic and hypercapnic ventilatory drives in man11 led investi- 
gators to study the effects of the endogenous opioid peptides on 
ventilation. The endogenous opioid peptides (met-enkephalin, 
leu-enkephalin, beta-endorphin, and others) are commonly referred 
to as endorphins ("endogenous morphine"). These peptides exert 
opiatelike actions by way of specific interactions with opioid 
receptors. They are present in brain pituitary gland, adrenal 
gland, plasma, and other tissues. 12-14 Indeed, although several 
studies indicate that endorphins are not involved in the regulation 
of ventilation in normal adult humans, 15-17 they cause respiratory 
depression, decreased ventilatory drive,lS-19 and apnea20 in 
animals and ventiIatory disorders in some pathophysiologic states 
in man.21922 
The unique characteristics of SIDS, in particular the quiet, 
sudden death during presumed sleep,gB23 led us to investigate 
the possibility that overactivity of the endogenous opioid system 
may cause SIDS.24 TO our knowledge, this is the first reported 
study of the endogenous opioid system in SIDS. 
METHODS 
Collection of Tissue. Postmortem tissue from SIDS victims and 
control infants was collected (by T.E.K.) with the assistance of 
Dr. Haruo Okazaki and the pathology staff of the Mayo Clinic, 
Rochester, Minnesota, and by Dr. Ralph Franciosi, Children's 
Health Center and Hospital, Minneapolis, Minnesota. One of us 
(T.E.K.) also collected cases from the Cook County Morgue with the 
cooperation of Dr. Robert J. Stein, Chief Medical Examiner, 
Cook County, Chicago, Illinois. All autopsies were done within 24 
hours of death except in one case. 
ControI Cases. The control cases were infants between the 
ages of two weeks and 12 months who died from accidental causes or 
congenital cyanotic heart disease and who had grossly normal brains 
at autopsy. The cases of congenital cyanotic heart disease serve 
as examples of known chronic hypoxemia and will be referred to as 
"hypoxic controls." 
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Handling. The fresh, unfixed tissue was dissected at the time 
of autopsy and deep frozen at -70°C until analysis. Samples were 
taken from brain, lung (right upper lobe), and adrenal gland. In 
some cases, one cerebral hemisphere (the left in most cases) was 
frozen whole and stored at -70°C. Dissection was subsequently done 
in a cold room at 4°C after the cerebral hemisphere was allowed to 
thaw at 4°C; it was dissected while still firm. The tissue sections 
(kept on ice) were then immediately extracted. 
Stability Study. For assessment of the stability of met- 
enkephalin in postmortem human brain tissue, both caudate nuclei 
were removed from one brain within three hours of the time of 
death. One small piece from one of the caudates was immediately 
frozen, and the remaining piece was refrigerated at 2 to 4°C. The 
other caudate was left at room temperature (21 to 22°C). At 5, 8, 
12, 19, and 24 hours after the time of death, a small slice from 
each caudate was frozen and stored at -70°C until analysis. 
Tissue Extraction Procedure for Met-Enkephalin and Beta- 
Endorphin. The deep-frozen tissue samples were allowed to thaw at 
4"C, weighed, added to plastic test tubes containing 10 volumes of 
1 M acetic acid (which had been preheated to 98'C), and heated at 
98°C for 15 minutes.25326 The solution was cooled on ice for a 
minimum of 10 minutes and then homogenized at 0°C (Polytron homo- 
genizer, setting 7, 30 seconds). The homogenate was centrifuged at 
10,000 x g for 20 minutes at 4"C.25 At this point an aliquot of 
the supernatant was lyophilized and stored at -20°C for future 
beta-endorphin determination. The remainder of the supernatant was 
applied to a C-18 column (Sep-Pak cartridge) that had been prewashed 
with 5 ml of absolute methanol and 12 ml of water. Then the column 
was washed with 4 ml of 1 M acetic acid and 4 ml of water and the 
eluates were discarded. The met-enkephalin-like material was 
eluted from the column with 4 ml of absolute methanol, which was 
subsequently removed by negative pressure on the Evapo-Mix device 
(modified method of Gilbert and associates).27 The residue, a 
crude tissue extract containing enkephalins, was stored at -20°C 
until analysis. Plasticware or silanized glassware was used for 
all the above steps. 
For an estimate of the recovery of met-enkephalin-like material 
from the tissue by the extractive procedure, 2 to 4 ng of synthetic 
met-enkephalin was separately processed in parallel with tissue 
samples, and the amount recovered was measured by radioimmunoassay. 
Interassay variability was determined by (1) repeated extraction 
and radioimmunoassay of remaining frozen tissue that was not used 
in the initial extraction; and (2) resuspension of some of the 
stored lyophilized supernatants and application to a C-18 column 
followed by radioimmunoassay for met-enkephalin. 
Radioimmunoassay. The amount of met-enkephalin or beta- 
endorphin immunoreactive material in the tissue extracts was 
determined by radioimmunoassay performed with met-enkephalin kits 
and beta-endorphin kits from Immune Nuclear Corporation, Stillwater, 
MN. Triplicate radioimmunoassay determinations were done on each 
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extract (quadruplicates were done for some extracts). The amount 
of lz51-labeled met-enkephalin bound to antibody in the reaction 
precipitates was measured (LKB 1275 mini gamma counter). The best 
fit for the standard curve and the potency estimates for each 
unknown sample were computed.27 
The radioimmunoassay for met-enkephalin was reported to have 
1.6% cross-reactivity for leu-enkephalin. Cross reactivities for 
beta-endorphin, substance P, gamma endorphin, and alpha-endorphin 
are all less than 0.01%. The sensitivity was 8 pg (14 fmol). 
The beta-endorphin measurements in lung tissue were performed 
on the lyophilized supernatants resuspended in radioimmunoassay 
buffer on ice. Beta-lipotropin, which cross reacts with the 
anti-beta-endorphin antibody, was stripped from the sample by 
affinity gel extraction that utilized a sepharose-antibody complex 
s ecific for the N-terminal of beta-lipotropin. 
J5 - 
The amount of 
I labeled beta-endorphin bound to antibody in the reaction 
precipitates was measured, and the data were handled in the same 
manner as for met-enkephalin. 
The radioimmunoassay for beta-endorphin was reported to have 
100% cross reactivity with both DES-Tyrl-human beta-endorphin and 
2-Me-Ala2-beta-endorphin, and 50% cross reactivity with human 
beta-lipotropin. Cross reactivities with leu-enkephalin, met- 
enkephalin, ACTH, dynorphin, alpha-endorphin, and gamma-endorphin 
are all less than 0.1%. The sensitivity was 2 pg (1 fmol). 
Since no extensive chemical characterization was done, the 
measured activity can only be attributed to "radioimmunoassayable 
material." 
For two-sample comparisons, both the two-sample t test and the 
rank-sum test were performed. For paired or one-sample comparisons, 
the paired J_ test and the signed-rank test were used. The two-tail 
level of significance was taken as the conventional 0.05. When 
significance differed, depending on the statistical procedure, both 
results are reported; otherwise, for brevity, only the t test 
results are noted if they agreed. 
RESULTS 
Extraction Procedure and Radioimmunoassay. The percent 
recovery of met-enkephalin by our extraction procedure was SO to 
90% (n = 4) as determined by radioimmunoassay. The triplicate 
radioimmunoassay dilutions were within 10% of their mean. Inter- 
assay variability was less than 10%. 
Confirmation of Cases. The final results of the autopsies and 
postmortem studies by the pathologist in all the cases of SIDS 
confirmed the diagnosis of SIDS (that is, results of toxicologic, 
bacteriologic, and viral studies were negative). 
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Stability of Met-Enkephalin in Postmortem Tissue. The met- 
enkephalin content in human caudate tissue obtained within three 
hours after the time of death was 820 + 5O/pmol/g wet weight (X + 
SD). This was not significantly different from the content in - 
tissue that was left at room temperature (21°C) for 19 hours after 
death (820 + 105 pmol/g), in tissue 24 hours after death (1,097 
pmolfg), or in tissue refrigerated for 21 hours at 4°C (b&ginning 
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Fig. 1 Met-enkephalin levels in human caudate tissue in relation 
to time after death. Earliest point is 3 hours after death. Each 
point represents concentration in a single slice of tissue. High 
point at 12 hours in sample kept at room temperature may be due to 
regional difference in particular slice of tissue assayed. 
The high value (1,893 pmol/g) in the sample kept at 21°C (the 
12-hour sample) may represent a regional difference in the partic- 
ular slice of caudate which was assayed, since one piece of tissue 
was used for each point. These data are consistent with the 
remarkable stability of enkephalin noted by Emson and colleagues,28 
who demonstrated no significant change in met-enkephalin content 
for up to 72 hours after death in mouse brains that were gradually 
cooled in a manner designed to simulate normal postmortem handling 
of human brains. 
Met-Enkephalin in Adult Brain. To check our extraction 
procedure, we studied adult brain tissue because the regional 
distribution of met-enkephalin cont;;t2in adult brain had been 
mapped out by two different groups. 9 Our results were 
similar to those that have been reported in both absolute values 
and regional distribution (Table 1). Highest levels of met-enkepha- 
lin were found in the caudate nucleus, globus pallidus, and sub- 
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42 Very low 
(16) 
116 1,000 - 
(20)*-k 2,000 (4) 
1,163 (40) 1,000 - 
(lateral) 2,000 (5) 
675 (40) 
(medial) 






*Numbers in parentheses are numbers of cases. 
**This low value may reflect a regional anatomic 
difference due to dissection technique. 
Met-Enkephalin in Infant Brain. Generally, the values in the 
five brain areas studied varied considerably (except the medullas) 
in both SIDS victims and controls (Table 2). Interpretation is 
made more difficult by the fact that there is only one report of 
these values in childhood,** and values for infants less than one 
and a half years old have not been previously reported. On inspec- 
tion, the values did not show any apparent relationship to sex, 
race, or source of the case. Generally, values in SIDS and controls 
were similar. In the cortex, no apparent changes occurred with age 
(n = 8). Levels in the caudate were lower than values in adults by 
a factor of about 10 but were similar to the values in children one 
and a half to two years old reported by Brandt and associates.** 
Met-Enkephalin in Infant Medullas. The average met-enkephalin 
content in the medullas of the SIDS group was 32 pmol/g tissue 
(SD = 14, n = 14). This was not significantly different from all 
controls-- 31 pmol/g (SD = 23, n = 6)--or from the hypoxic control 
group--42 pmol/g (SD = 17, n = 4). The average met-enkephalin 
content in the medullas of the SIDS group was significantly higher 
than that of the trauma controls, which was 8 pmol/g (SD = 4, 
n = 21, P = 0.033; however, this difference is not interpretable 
because zf the older age (11 months and 12 months) and small number 
(n = 2) of the trauma controls (Table 3). 
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Table 2 
Infant Brain Met-Enkephalin Levels 
(Picomoles of Met-Enkephalin per Gram Wet Weight of Tissue) 
Age (mo) 1 l-1/2 3 3-l/2 
SIDS or 
control 




P/W M/B M/W F/W M/W F/B 











4 a 10 13 17 18 19 20 
Petechiae present 
on thymus or pleura 
Cortex (frontal) 
Yes NO Yes No No Yes 
















27 ___ 85 ___ 
35 26 61 16 
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*c.c. = Cook County, Chicago, Illinois; Mpls. = Minneapolis, Minnesota; Olm = Olmsted 
County, Minnesota; Mayo = case referred to Mayo Clinic. 
**Values reported by Brandt and associates 
22 
for three controls: 1-l/2-year-old, 
2-year-old, and L-year-old (congenital heart disease); numbers in paretheses = number 
of control cases. 
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Table 3 
Levels of Met-Enkephalin in Medullas From 20 Infants 




present (or average 
Age Cause of Source of on thymus Medial Lateral of medial and 











































































































































In the 16 cases in which the met-enkephalin content of the 
medial and lateral sides of the medulla was determined, the tendency 
(14 of 16) was for the medial medulla content to be equal to or 
greater than that of the lateral medulla. This reached statistical 
significance when the signed-rank test (P = 0.032) was used but not 
with the paired t test. In nine cases tee difference between the 
medial and the lateral medulla was only 3 pmol or less (Table 3). 
Met-Enkephalin in Adrenal Tissue. Small amounts of met-enkepha- 
lin were present in sections from the adrenal gland (containing 
tissue from both the adrenal cortex and the adrenal medulla). Two 
SIDS cases, one and a half months and three and a half months of 
age, had values of 18 and 1 pmol/g wet weight of tissue, respectively. 
Two controls with congenital cyanotic heart disease, three and a 
half months and nine months of age, had values of 8 and 0.6, 
respectively. A pronounced difference between SIDS cases and 
control cases was not apparent, and these values are much lower 
than the few values that have been reported in adults.14 There 
are no reports of met-enkephalin levels in infant adrenal glands 
available for comparison. 
Beta-Endorphin and Met-Enkephalin in Lung Tissue. Small 
amounts (femtomolar range) of beta-endorphin and met-enkephalin 
were present in infant lung tissue (Table 4). Although we did not 
specifically study the stability of beta-endorphin, in the seven 
cases in which it was assayed, the values were all very similar and 
did not show any relationship to the elapsed time between death and 
autopsy. This finding is consistent with a previous report which 
also suggests that beta-endorphin immunoreactive material is 
stable with respect to time after death.29 We cannot rule out 
the possibility however, that these low values may represent a 
postmortem artifact. 
Table 4 
Beta-Endorphin and Met-Enkephalin 
in Lung Tissue* 
Levels 
Age Case Beta- Met- 






























CCHD = Congenital Cyanotic Heart Disease. 
*All values are in femtomoles per gram wet 
weight of tissue, + approximately 20%. 
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When the concentration of met-enkephalin in the medullas of 
all infants studied (n = 20) was compared with respect to age, the 
concentration was found to decrease significantly with increasing 
age (P = 0.008). The linear relationship between the levels in the 
medulla and age was not detectably different in SIDS and controls. 
However, as a subset, the met-enkephalin concentration in the 
medullas of the SIDS cases (n = 14) showed no change bith respect 
to age (r = -0.28, P = 0.331, whereas the control group (n = 6) 
showed a-significant (L= -0.94, P = 0.005) decrease with increasing - 
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Scatter diagram of average medulla met-enkephalin concen. 
versus age. 
LEGEND 
*Total number of SIDS cases = 
number of control cases = 6: 4 
and 2 trauma controls (1 boy, 1 
heart disease. 
""C.C. = Cook County, Chicago, 
FOR TABLE 3 
14 (7 boys, 7 girls); total 
hypoxic controls (2 boys, 2 girls) 
girl); CCPH = congenital cyanotic 
Illinois; Mpls = Minneapolis, 
Minnesota; Olm = Olmsted County, Minnesota; Mayo = case referred to 
Mayo Clinic. 
***Died 15 minutes after surgery for total anomalous pulmonary 
venous return; anesthetics were pancuronium bromide and fentanyl; 
had low PD2 before death. 
'WDied 6 days after surgery for complete atrioventricular canal; 
sustained cardiac arrest and as a result suffered a severe anoxic 
insult; pupils were fixed and dilated; had spontaneous respirations 
but no other detectable neurologic function. 
lTCompfete abdominal and thoracic situs inversus, double-outlet 
right ventricle; did not have surgery. 
Yq'IDied 4 days after surgery for complete transposition of the 
great vessels; low PC before death; neuropathology revealed 
acute hypoxic encepha opathy. ? 
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The one-and-a-half-month-old SIDS case had a very high level 
of met-enkephalin in comparison with the three other cases; however, 
such a value was not seen in the three-and-a-half-month-old SIDS 
case, and it may reflect an age-related change. There are no 
reports of levels of these peptides in human lung tissue available 
for comparison. 
DISCUSSION 
A considerable advance in our understanding of SIDS came in 
1973 when Naeye30 reported that smooth muscle fibers in small 
pulmonary arteries were commonly both hyperplastic and hypertrophied 
in this condition. There is evidence suggesting that this finding 
and other subtle tissue abnormalities noted in SIDSl are a 
result of chronic hypoxemia, 
before death from S1Ds.l~~ 
which may be present weeks or months 
Studies of infants deemed "near-miss" 
for SIDS* also suggest that abnormal ventilatory control may be a 
factor in the pathogenesis of SIDS.31-34 
These findings and other clinical observations are consistent 
with the apnea hypothesis of SIDS proposed by Steinschneider 
in 1972 and have recently been well reviewed.3,5,9,36,37 Most 
investigators agree that protracted apnea, especially during sleep, 
plays a role in many cases of SIDS.3,5,9 However, the cause of 
the apnea and the subsequent silent, sudden death is unknown. 3,36 
Clinically imperceptible hypoventilation with substantial 
depression of hypercapnic and hypoxic ventilatory drive has 
been reported in conscious, awake men after administration of only 
7.5 mg of morphine subcutaneously.ll Thus, it was not surprising 
when, in 1977, Florez and Mediavilla demonstrated that an 
endogenous opioid peptide (met-enkephalin) produced a naloxone- 
reversible (naloxone blocks the effects of endogenous opioid 
peptides) respiratory depression when applied to the ventral 
surface of the cat brain, an effect subsequently noted to be 
elicited by beta-endorphin as we11.39 Moss and associates 
demonstrated in 1978 that elevation of beta-endorphin levels by 
direct injection into the cisterna magna of adult dogs produced a 
naloxone-reversible respiratory depression and a reduced central 





peptides may be involved in the pathogenesis of 
In humans, several studies have indicated that endogenous 
opioid peptides are not involved in the regulation of ventilation 
in normal adults.15-17 However , participation of the endogenous 
opioid system in the control of breathing in unanesthetized human 
beings with obstructive airway disease has recently been demon- 
strated.21,42 
*These are infants noted by a caretaker to be apneic y limp, 
and pale or cyanotic who require vigorous shaking or cardiopulmonary 
resuscitation to restore respirations and for whom a subsequent 
rigorous medical evaluation fails to reveal the cause of the 
episode.9 
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Kuich and Zimmerman24,43 have proposed that SIDS and 
near-SIDS may be caused by overactivity of the endogenous opioid 
system. In addition to respiratory depression and apnea the 
endorphin overactivity as shown by Brandt and associates 12 may 
also provide an element of supraspinal analgesia and thus account 
for a quiet death during presumed sleep. 
We found that in cortex, subcortex, caudate nucleus, medulla, 
lung, and adrenal tissue there were no pronounced differences in 
met-enkephalin levels in cases of SIDS in comparison with controls 
(Table 2). Levels in the cortex, subcortex and caudate nucleus 
varied widely between cases. The values were not remotely close to 
the very elevated levels found in the hyperendorphin case reported 
by Brandt and associates,** but were similar to the control 
values which they reported (Table 2). Within a given brain, 
values in different regions were variously increased or decreased 
in comparison with the same regions in other brains. This indicates 
that in SIDS there is no generalized increase in met-enkephalin 
levels as a secondary response to hypoxia or as a primary event in 
the pathogenesis of this condition. 
Overactivity of the endogenous opioid system may occur as a 
result of several mechanisms: supersensitivity of the receptors, 
increased number of receptors, defective degradation or inactivation 
of the peptides, abnormal "enkephalinase" activity,44 or over- 
production. In fact, even sudden death associated with exogenous 
opiate abuse may not necessarily be a dose-related phenomenon. 45,46 
Current data suggest that drug 
failure of tolerance.47 Thus, 
"overdose" may often result from a 
the lack of a pronounced difference 
in met-enkephalin levels between SIDS cases and controls does not 
decrease the likelihood of primary involvement of the endogenous 
opioid system in the pathogenesis of SIDS, since only overproduction 
and perhaps defective degradation of met-enkephalin were addressed 
by the present study. 
Rhythmic respiratory drive is believed to be generated by 
various nuclei in the medulla.48 
these nuclei,13 
Opiate receptors are found in 
and enkephalins are present in the medulla.25,*8 
For these reasons, the met-enkephalin content in the medulla6 of 
SIDS victims is of particular interest. In comparison with the 
variation found in the other brain areas, met-enkephalin content in 
the medullas of SIDS victims was within a narrow range (10.5 to 61 
pmol/g); 9 of 14 cases (64%) had between 26 and 40 pmol/g (Table 
3). Medulla met-enkephalin levels in the SIDS cases were not 
detectably different from those in the hypoxic control group. Both 
SIDS cases and the hypoxic controls had levels higher than the 
trauma controls. However, direct comparison with the traumatic 
control values is made difficult by the small number of cases 
(two), their older age (11 months and 12 months), and the observed 
inverse relationship with age. Although all the medulla values may 
be well within a normal range, it is curious that values in infants 
dying from a quiet, sudden death would have levels that are indis- 
tinguishable from those in infants dying of severe congenital 
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cyanotic heart disease with the stressful histories noted in Table 
3, since the endogenous opioid system may be activated by stress.49 
Thus, it is possible that both the SIDS values and the chronically 
hypoxic control values are abnormally high, but more study is 
needed. 
The levels of met-enkephalin and beta-endorphin in the lungs 
of SIDS victims are of great interest because of recent reports 
that enke halin analogues stimulate pulmonary J-receptors in 
rats.*50,F1 The reflex produced by J-receptor stimulation causes 
a decrease in blood pressure, increased laryn eal resistance, 
* 52-54 
and 
apnea, Sapru a~~l~~:~~i",~e~~~~~pnea and bradycardia. Specifically, 
demonstrated that enkephalin analogues 
injected into the right atrium of decerebrate rats stimulated 
pulmonary J-receptors and produced bradycardia and apnea within 1 
to 2 seconds. Apnea was followed by rapid, shallow breathing. The 
duration of apnea was dose-related, could be blocked by pretreatment 
with naloxone, and was not observed with physiolo ic saline injec- 
tion. Beta-endorphin caused these same effects. 55 Also noted was 
a naloxone-reversible increase in laryngeal and lung resistance.56,57 
Although these results should be interpreted with caution,5* 
these reports are fascinating, and if they are confirmed by other 
groups they would provide an attractive mechanism for the patho- 
genesis of SIDS. In fact, the possibility that prolonged apnea in 
infancy may result from activation of pulmonary J-receptors 
has been previously noted.59 
Plasma beta-endorphin levels show a clear diurnal variation in 
adults, with a two-fold difference between peak and trough levels.60 
The peak plasma values of beta-endorphin in adults occur between 4 
a.m. and 10 a.m. This is the same time of day that SIDS is most 
commonly noted to occur.9,61 Whether such a diurnal variation 
in plasma values occurs in infancy is unknown, but it is tempting 
to speculate that the apnea noted in normal infants, the increased 
duration and frequency of apnea in infants who have had a near miss 
for SIDS, and the terminal apnea in SIDS victims may all be due to 
differing degrees of stimulation of pulmonary J-receptors by early 
morning peaks of plasma beta-endorphins. This would explain the 
circadian distribution of apnea (peak between 1 a.m. and 6 a.m.) 
which has been noted during 24-hour monitoring in infants.' 
Such a mechanism would also account for the case reports of 
sudden death in infants with congenital adrenal hypoplasia.62,63 
These infants would be expected to have high levels of ACTH (in the 
one case in which it was measured it was elevated),62 which, 
would be accompanied by elevated plasma levels of 
;~;",'~~d$;;'s4,65 
*There are three types of pulmonary receptors (vagal affer- 
ents): stretch, irritant, and unmyelinated J-receptors. Although 
there are some species variations, the general characteristics of 
these receptors are similar for man, cat, rabbit, and dog.52953 
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Very small (femtomolar range) but measurable amounts of 
methionine-enkephalin and beta-endorphin were found in lung tissue 
from SIDS and control infants (Table 4). We expected that measur- 
able levels of these peptides would be present in human lung tissue 
because of earlier reports of enkephalins66 and opiate receptors67 
in mammalian lungs, and from the immunohistochemical demonstration 
of leu-enkephalin in endocrine cells of lung tissue from human 
fetuses, newborns, children, and adults. 68 
The values of beta-endorphin which we found in lung tissue 
(315 to 639 fmol/g wet weight of tissue) are considerably higher 
than values reported in human plasma (adults 4 fmol/ml plasma;60265 
cord blood, approximately 16 fmol/ml plasma; 69,70 term amniotic 
fluid, approximately 20 fmol/m170). The levels of met-enkephalin 
in 1 g wet weight of lung tissue ranged from 520 to 11,000 fmol, 
which is very low in comparison with levels in brain tissue 
and is similar to values found in 1 ml of plasma (approximately 100 
fmol of met-enkephalin per milliliter of plasma).71 There was 
no difference between SIDS and control infants with regard to the 
levels of met-enkephalin or beta-endorphin in lung tissue (Table 
4). This finding suggests that if pulmonary J-receptor activation 
is involved in the pathogenesis of SIDS, postmortem evidence for 
such involvement cannot be derived from radioimmunoassay of lung 
tissue extracts by means of the method described. Plasma levels of 
beta-endorphin in near-SIDS infants or postmortem plasma levels of 
beta-endorphin in SIDS victims may be more revealing. 
It is interesting to note the similarities in pulmonary 
pathology found in SIDS victims and in cases of sudden death due to 
opiate abuse--pulmonary edema is common in both instances.72,73 
Frothy hemorrhagic fluid in the tracheobronchial tree and around 
the mouth and nose has been reported in 56% of SIDS cases.72s74 
Frothy fluid around the mouth is also commonly found among4;d;fcts 
who have experienced sudden death due to opiate injection. 3 
Petechial hemorrhages under the pleura have been noted in SIDS 
infants75 and also among heroin addicts who have died suddenly.76 
Although these similar pathologic findings may result from a 
completely different pathophysiology, or from similar pathophysiology 
but different etiology, the similarities in pathology are inter- 
esting in light of our hypothesis and have not been previously noted. 
The vulnerability of the infant to SIDS between the ages of 
two months and four months may be related to a postnatal ontogenic 
development of the endogenous opioid system. Several studies 
suggest that there is a postnatal ontogenic development of the 
endogenous opioid system in rats.77-7g Administration of 
morphine or naloxone to female rats before and during pregnancy has 
been shown to alter significantly the normal postnatal regional 
pattern of development of [3H]met-enkephalin binding sites in the 
brains of offspring.7g If SIDS was caused by an abnormality of 
the endogenous opioid system, then these studies, which suggest 
that maternal opiate abuse perturbs the normal ontogeny of the 
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endogenous opioid system in offspring, would explain the strikingly 
increased incidence of SIDS among infants of mothers addicted to 
opiates or on methadone maintenance. 80-82 
CONCLUSIONS 
Primary involvement of the endogenous opioid system in the 
pathogenesis of SIDS provides an attractive mechanism for silent, 
sudden, infant death. Careful consideration of our present knowledge 
of SIDS and the endogenous opioid system yields a hypothesis that 
coherently explains all of the unique features of SIDS. We assayed 
various tissues for met-enkephalin and lung tissue for beta-endorphin. 
No pronounced differences in met-enkephalin levels between SIDS and 
control infants were apparent. However, further study of the rate 
of change in medullary met-enkephalin concentration with respect to 
age is indicated. 
Given the inherent difficulties associated with postmortem 
analysis and the attendant problems of data interpretation, a 
clinical study using naloxone in near-miss infants may be the most 
definitive way of assessing the role of endogenous opiates in SIDS 
and near-SIDS. 
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